147 related articles for article (PubMed ID: 10943319)
1. CpG oligonucleotides as immune adjuvants.
Krieg AM
Ernst Schering Res Found Workshop; 2000; (30):105-18. PubMed ID: 10943319
[No Abstract] [Full Text] [Related]
2. Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides.
Krieg AM
Biochim Biophys Acta; 1999 Dec; 1489(1):107-16. PubMed ID: 10807001
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic applications of CpG-containing oligodeoxynucleotides.
Klinman DM
Antisense Nucleic Acid Drug Dev; 1998 Apr; 8(2):181-4. PubMed ID: 9593061
[No Abstract] [Full Text] [Related]
4. Adjuvant activity of CpG oligodeoxynucleotides.
Klinman DM
Int Rev Immunol; 2006; 25(3-4):135-54. PubMed ID: 16818369
[TBL] [Abstract][Full Text] [Related]
5. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen.
Davis HL; Weeratna R; Waldschmidt TJ; Tygrett L; Schorr J; Krieg AM
J Immunol; 1998 Jan; 160(2):870-6. PubMed ID: 9551923
[TBL] [Abstract][Full Text] [Related]
6. The response of human B lymphocytes to oligodeoxynucleotides.
Liang H; Lipsky PE
Springer Semin Immunopathol; 2000; 22(1-2):63-75. PubMed ID: 10944801
[No Abstract] [Full Text] [Related]
7. Immunopharmacology of CpG DNA.
Dalpke A; Zimmermann S; Heeg K
Biol Chem; 2002 Oct; 383(10):1491-500. PubMed ID: 12452427
[TBL] [Abstract][Full Text] [Related]
8. Cytokine gene-engineered vaccines.
Forni G; Boggio K
Curr Opin Mol Ther; 1999 Feb; 1(1):34-8. PubMed ID: 11249681
[TBL] [Abstract][Full Text] [Related]
9. CpG motifs for optimization of DNA vaccines.
Davis HL
Dev Biol (Basel); 2000; 104():165-9. PubMed ID: 11713816
[TBL] [Abstract][Full Text] [Related]
10. Immunostimulatory oligonucleotides: ready for immunotherapy prime time!
Tam YK
J Hematother Stem Cell Res; 2003 Oct; 12(5):467-71. PubMed ID: 14594503
[No Abstract] [Full Text] [Related]
11. Three types of human CpG motifs differentially modulate and augment immunogenicity of nonviral and viral replicon DNA vaccines as built-in adjuvants.
Yu YZ; Li N; Ma Y; Wang S; Yu WY; Sun ZW
Eur J Immunol; 2013 Jan; 43(1):228-39. PubMed ID: 23037552
[TBL] [Abstract][Full Text] [Related]
12. MUC1- and Survivin-based DNA Vaccine Combining Immunoadjuvants CpG and interleukin-2 in a Bicistronic Expression Plasmid Generates Specific Immune Responses and Antitumour Effects in a Murine Colorectal Carcinoma Model.
Liu C; Xie Y; Sun B; Geng F; Zhang F; Guo Q; Wu H; Yu B; Wu J; Yu X; Kong W; Zhang H
Scand J Immunol; 2018 Feb; 87(2):63-72. PubMed ID: 29193199
[TBL] [Abstract][Full Text] [Related]
13. Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides.
Krieg AM
Curr Oncol Rep; 2004 Mar; 6(2):88-95. PubMed ID: 14751085
[TBL] [Abstract][Full Text] [Related]
14. CpG DNA is an effective oral adjuvant to protein antigens in mice.
McCluskie MJ; Weeratna RD; Krieg AM; Davis HL
Vaccine; 2000 Nov; 19(7-8):950-7. PubMed ID: 11115721
[TBL] [Abstract][Full Text] [Related]
15. Enhanced tumor-specific long-term immunity of hemagglutinating [correction of hemaggluttinating] virus of Japan-mediated dendritic cell-tumor fused cell vaccination by coadministration with CpG oligodeoxynucleotides.
Hiraoka K; Yamamoto S; Otsuru S; Nakai S; Tamai K; Morishita R; Ogihara T; Kaneda Y
J Immunol; 2004 Oct; 173(7):4297-307. PubMed ID: 15383558
[TBL] [Abstract][Full Text] [Related]
16. A candidate DNA vaccine elicits HCV specific humoral and cellular immune responses.
Zhu LX; Liu J; Ye Y; Xie YH; Kong YY; Li GD; Wang Y
World J Gastroenterol; 2004 Sep; 10(17):2488-92. PubMed ID: 15300890
[TBL] [Abstract][Full Text] [Related]
17. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization.
Weiner GJ; Liu HM; Wooldridge JE; Dahle CE; Krieg AM
Proc Natl Acad Sci U S A; 1997 Sep; 94(20):10833-7. PubMed ID: 9380720
[TBL] [Abstract][Full Text] [Related]
18. Superior activity of the type C class of ISS in vitro and in vivo across multiple species.
Marshall JD; Fearon KL; Higgins D; Hessel EM; Kanzler H; Abbate C; Yee P; Gregorio J; Cruz TD; Lizcano JO; Zolotorev A; McClure HM; Brasky KM; Murthy KK; Coffman RL; Nest GV
DNA Cell Biol; 2005 Feb; 24(2):63-72. PubMed ID: 15699627
[TBL] [Abstract][Full Text] [Related]
19. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity.
Davila E; Celis E
J Immunol; 2000 Jul; 165(1):539-47. PubMed ID: 10861094
[TBL] [Abstract][Full Text] [Related]
20. CpG motifs are efficient adjuvants for DNA cancer vaccines.
Schneeberger A; Wagner C; Zemann A; Lührs P; Kutil R; Goos M; Stingl G; Wagner SN
J Invest Dermatol; 2004 Aug; 123(2):371-9. PubMed ID: 15245438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
